In healthcare legislation, the most consequential changes often arrive quietly: tucked into definitions or buried in amendments. For healthcare organizations, that means the difference between proactive engagement and reactive...
Read moreSuccessor-in-Interest (SII) transitions are among the most demanding regulatory and operational projects an organization can undertake. Whether driven by a merger and acquisition or an organizational shift, these transitions...
Read morePolicies and practices around informed consent for substance use disorder treatment in Idaho that were defensible for the last several years may no longer align with current state and...
Read moreRevenue cycle management (RCM), the financial process of tracking patient care, is where even the best-run healthcare organizations can lose significant revenue. Whether due to misunderstood rules, outdated processes,...
Read moreThe 340B Drug Pricing Program allows eligible healthcare providers, known as covered entities, to purchase certain outpatient drugs at reduced prices from pharmaceutical manufacturers. These savings can help covered...
Read moreThe 340B drug program allows certain covered entities, to purchase outpatient drugs at discounted prices from pharmaceutical manufacturers. As a result, the covered entities can reach more eligible patients,...
Read moreThis blog is not legal advice and does not create an attorney-client relationship with our firm. The content is intended to promote a general understanding of legal concepts and should not be relied upon as a substitute for obtaining legal advice from a qualified attorney regarding the reader’s specific circumstances. Readers should consult legal counsel for advice concerning their individual situations. All content is provided without any representations or warranties regarding completeness, accuracy, or timeliness.